X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with ALEMBIC PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ALEMBIC PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA ALEMBIC PHARMA SANOFI INDIA/
ALEMBIC PHARMA
 
P/E (TTM) x 30.0 26.1 114.9% View Chart
P/BV x 5.3 6.0 89.0% View Chart
Dividend Yield % 1.7 0.8 215.3%  

Financials

 SANOFI INDIA   ALEMBIC PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
ALEMBIC PHARMA
Mar-16
SANOFI INDIA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs4,560792 576.0%   
Low Rs4,400443 993.2%   
Sales per share (Unadj.) Rs1,028.5167.0 615.8%  
Earnings per share (Unadj.) Rs129.038.2 337.9%  
Cash flow per share (Unadj.) Rs186.042.0 442.9%  
Dividends per share (Unadj.) Rs68.004.00 1,700.0%  
Dividend yield (eoy) %1.50.6 234.3%  
Book value per share (Unadj.) Rs753.684.9 887.7%  
Shares outstanding (eoy) m23.03188.52 12.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.43.7 117.8%   
Avg P/E ratio x34.716.2 214.7%  
P/CF ratio (eoy) x24.114.7 163.9%  
Price / Book Value ratio x5.97.3 81.8%  
Dividend payout %52.710.5 503.1%   
Avg Mkt Cap Rs m103,174116,383 88.7%   
No. of employees `0003.6NA-   
Total wages/salary Rs m3,5924,214 85.2%   
Avg. sales/employee Rs Th6,537.7NM-  
Avg. wages/employee Rs Th991.4NM-  
Avg. net profit/employee Rs Th819.8NM-  
INCOME DATA
Net Sales Rs m23,68631,487 75.2%  
Other income Rs m70855 1,284.9%   
Total revenues Rs m24,39431,542 77.3%   
Gross profit Rs m5,28110,060 52.5%  
Depreciation Rs m1,313722 181.8%   
Interest Rs m1537 40.8%   
Profit before tax Rs m4,6619,356 49.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6912,160 78.3%   
Profit after tax Rs m2,9707,194 41.3%  
Gross profit margin %22.331.9 69.8%  
Effective tax rate %36.323.1 157.1%   
Net profit margin %12.522.8 54.9%  
BALANCE SHEET DATA
Current assets Rs m15,67315,066 104.0%   
Current liabilities Rs m6,6787,674 87.0%   
Net working cap to sales %38.023.5 161.8%  
Current ratio x2.32.0 119.6%  
Inventory Days Days7667 113.5%  
Debtors Days Days2241 54.9%  
Net fixed assets Rs m8,0988,237 98.3%   
Share capital Rs m230377 61.1%   
"Free" reserves Rs m17,08815,416 110.8%   
Net worth Rs m17,35616,005 108.4%   
Long term debt Rs m00-   
Total assets Rs m25,40024,594 103.3%  
Interest coverage x311.7255.2 122.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.91.3 72.8%   
Return on assets %11.829.4 40.0%  
Return on equity %17.144.9 38.1%  
Return on capital %26.958.7 45.9%  
Exports to sales %24.555.7 43.9%   
Imports to sales %28.010.4 268.3%   
Exports (fob) Rs m5,80117,551 33.1%   
Imports (cif) Rs m6,6273,283 201.9%   
Fx inflow Rs m7,14517,811 40.1%   
Fx outflow Rs m6,8465,318 128.7%   
Net fx Rs m29912,493 2.4%   
CASH FLOW
From Operations Rs m3,2269,304 34.7%  
From Investments Rs m-1,555-3,105 50.1%  
From Financial Activity Rs m-1,818-1,959 92.8%  
Net Cashflow Rs m-1474,240 -3.5%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 2.9 496.6%  
FIIs % 14.6 9.1 160.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 13.9 75.5%  
Shareholders   15,184 49,328 30.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFE  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Aug 23, 2017 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - ASTRAZENECA PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS